Completed PHASE1 INTERVENTIONAL 1-arm NCT00424710

Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) (PEARL)

Phase I Study of Ranibizumab Injection for Polypoidal Choroidal Vasculopathy (PEARL)

Sponsor: Genentech, Inc.

Conditions Polypoidal Choroidal Vasculopathy

Interventions ranibizumab intravitreal injection

Updated 7 times since 2017 Last updated: Nov 3, 2014 Started: Jan 31, 2007 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Polypoidal Choroidal Vasculopathy and is currently completed. Genentech, Inc. leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Hawaii Pacific Health

Data source: Hawaii Pacific Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Honolulu, United States
• ‘Aiea, United States